RFA-HL-26-019-Full-Announcement.html

This document is a Request for Application (RFA) for the NHLBI Catalyze Product Definition medical device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed) grant opportunity.

The goal of this initiative is to provide early-stage translational support for activities required to develop and test device prototypes, identify diagnostic disease targets and develop associated assays, and develop research tools to treat HLBS diseases and disorders. The program has two phases - the R61 phase provides funding to identify and test initial prototype designs, identify a disease target, and pilot research tools, while the R33 phase supports continued prototype development and testing, diagnostic product generation, assay component exploration, and research tool improvement. Eligible applicant types include tribal organizations, higher education institutions, nonprofits, small businesses, and state/local governments. The grant is funded through the NHLBI's Lung Diseases Research, Cardiovascular Diseases Research, Blood Diseases and Resources Research, and National Center on Sleep Disorders Research programs. Following successful completion, the expectation is that the potential products will be ready for in vivo testing with additional support.